The significance of pan-immune inflammation value and systemic immune inflammation Index in colorectal cancer screening

Year 2021, Volume: 12 Issue: 3, 273 - 277, 29.09.2021

Sanem Kayhan , Özlem Aydın İsak

https://doi.org/10.18663/tjcl.985559

Cited By: 2

Abstract

Aim: It has been known for a long time that systemic inflammation is an important risk factor in cancer development. Colorectal cancer (CRC) is one of the most common causes of cancer-related morbidity and mortality in the world. In this study, we aimed to compare the inflammatory parameters tested in CRC patients at the time of diagnosis such as systemic immune-inflammation index (SII) and pan-immune inflammation value (PIV) with those of the healthy control group.
Materials and Methods: The data of 162 patients diagnosed with CRC in the internal medicine clinic between 2012-2016 were analysed retrospectively and a total of 139 patients who met the inclusion criteria were included in the study. Hemogram values, histopathology and tumour stage according to TNM classification of all patients at the time of diagnosis were recorded. The patients’ neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), SII and PIV were calculated using hemogram parameters such as neutrophils, monocytes, platelets and lymphocytes.
Results: A total of 139 CRC patients and 139 healthy control subjects with similar age and sex distribution were included in the study. The mean age of all subjects included in the study was 61.7±11.8 years, and 170 subjects (61.2%) were male. In the CRC group, SII, PIV, NLR, and PLR levels were significantly higher, and LMR level was significantly lower than the control group (p<0.001, p<0.001, p<0.001, p<0.001, p=0.001, respectively). When the CRC group was divided according to the disease stage, it was found that SII and PIV levels of all stages were significantly higher than the control group (p= 0.029, p<0.001, p= 0.001, p= 0.002 for SII, p= 0.034, p<0.001, p= 0.002, p= 0.014 for PIV).
Conclusion: In addition to colonoscopy screening in patients with CRC, whose early diagnosis is very important, SII and PIV values that do not require an additional cost and can be measured in routine hemogram tests can also be taken into consideration.

Keywords

colorectal canser, systemic ımmune ınflammation index, pan-immune inflammation value

Kolorectal kanser taramasında panimmun inflamasyon değerinin ve sistemik immün-inflamasyon indeksinin önemi

Abstract

Amaç:Sistemik inflamasyonun kanser gelişiminde önemli bir risk faktörü olduğu uzun zamandır bilinmektedir. Kolorektal kanser (CRC) de dünyada kanser ilişkili morbidite ve mortalitenin en sık nedenlerinden biridir. Bu çalışmada CRC’li hastalarda tanı anından bakılan sistemik immün-inflamasyon indeksi (SII) ve panimmun inflamasyon değeri (PIV) gibi inflamatuar parametrelerin sağlıklı kontrol grubu ile karşılaştırmayı amaçladık.
Gereç ve Yöntemler:2012-2016 yılları arasında dahiliye kliniğinde CRC tanısı alan 162 hastanın verileri retrospektif olarak incelendi ve dahil edilme kriterlerini sağlayan toplam 139 hasta çalışmaya dahil edildi. Tüm hastaların tanı anında bakılan hemogram değerleri, histopatolojisi ve TNM sınıflamasına göre tümör evreleri kaydedildi. Hastaların nötrofil-lenfosit oranı (NLR), platelet-lenfosit oranı (PLR), lenfosit-monosit oranı (LMR), SII ve PIV, nötrofiller, monositler, trombositler ve lenfositler gibi hemogram parametreleri kullanılarak hesaplandı.
Bulgular: Çalışmaya 139 CRC’li hasta ile yaş ve cinsiyet dağılımı benzer olan 139 sağlıklı kontrol grubu dahil edildi. Çalışmaya dahil edilen tüm vakaların yaş ortalaması 61.7±11.8 olup 170’i erkek (%61.2) idi. CRC grubunda SII, PIV, NLR ve PLR düzeyleri kontrol grubuna göre anlamlı yüksek, LMR düzeyi anlamlı düşüktü ( sırası ile p< 0.001 p< 0.001 p< 0.001 p< 0.001p= 0.001). CRC grubu hastalık evresine göre ayrıldığında tüm evrelerin kontrol grubuna göre SII ve PIV düzeyleri anlamlı yüksekti (SII için p= 0.029 p< 0.001 p= 0.001 p= 0.002 PIV için p= 0.034 p< 0.001 p= 0.002 p= 0.014)
Sonuç: Erken tanısı büyük önem taşıyan CRC’li hastalarda kolonoskopik taramanın yanında, ek bir maliyet gerektirmeyen, rutin hemogram testi ile ölçülebilen SII ve PIV değerleri de dikkate alınabilir.

Keywords

Kolorektal kanser, sistemik immun-inflamasyon indeksi, panimmun inflamasyon değeri

References

• 1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018; 68: 394-424.
• 2. Gültekin M, Boztaş G. Türkiye kanser istatistikleri. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu. 2014; 43: 12-32.
• 3. Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. Annals of translational medicine. 2019; 7 :609.
• 4. Ilgaz AE, Gözüm S. Determination of Colorectal Cancer Risk Levels, Colorectal Cancer Screening Rates, and Factors Affecting Screening Participation of Individuals Working in Agriculture in Turkey. Cancer nursing. 2018; 41: 46-54.
• 5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.
• 6. Kim DK, Oh SY, Kwon HC, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC cancer. 2009; 9: 155.
• 7. Lasry A, Zinger A, Ben-Neriah Y. Inflammatory networks underlying colorectal cancer. Nature immunology. 2016; 17: 230-40.
• 8. Maeda K, Shibutani M, Otani H, Nagahara H, Ikeya T, Iseki Y, et al. Inflammation-based factors and prognosis in patients with colorectal cancer. World journal of gastrointestinal oncology. 2015; 7: 111-7.
• 9. Hong X, Cui B, Wang M, et al. Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. The Tohoku journal of experimental medicine. 2015; 236: 297-304.
• 10. Jomrich G, Gruber ES, Winkler D, et al. Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2020; 24: 610-8.
• 11. Dong M, Shi Y, Yang J, et al. Prognostic and clinicopathological significance of systemic immune-inflammation index in colorectal cancer: a meta-analysis. Therapeutic advances in medical oncology. 2020; 12: 1758835920937425.
• 12. Fucà G, Guarini V, Antoniotti C, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. British journal of cancer. 2020; 123: 403-9.
• 13. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008; 454: 436-44.
• 14. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012; 33: 949-55.
• 15. Gooden MJ, de Bock GH, Leffers N, et al . The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. British journal of cancer. 2011; 105: 93-103.
• 16. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer cell. 2011; 20: 576-90.
• 17. Karakasheva TA, Dominguez GA, Hashimoto A, et al. CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI insight. 2018; 3.
• 18. Yang R, Chang Q, Meng X, Gao N, et al. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. Journal of Cancer. 2018; 9: 3295-302.
• 19. Schumacher D, Strilic B, Sivaraj KK, et al. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer cell. 2013; 24: 130-7.
• 20. Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013; 123: 3446-58.
• 21. De Giorgi U, Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clinical breast cancer. 2012; 12: 264-9.
• 22. Abe T, Amano H, Kobayashi T, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018; 44: 1573-9.